Compare SELF & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SELF | FLNA |
|---|---|---|
| Founded | 1983 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 61.8M |
| IPO Year | 1997 | 2000 |
| Metric | SELF | FLNA |
|---|---|---|
| Price | $5.52 | $0.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 29.1K | ★ 312.7K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | $12,705,245.00 | ★ $41,119,000.00 |
| Revenue This Year | $3.04 | N/A |
| Revenue Next Year | $3.47 | N/A |
| P/E Ratio | $50.45 | ★ N/A |
| Revenue Growth | ★ 1.40 | N/A |
| 52 Week Low | $4.73 | $0.85 |
| 52 Week High | $5.63 | $2.03 |
| Indicator | SELF | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 60.00 | 45.92 |
| Support Level | $4.99 | $0.86 |
| Resistance Level | $5.63 | $1.05 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 71.69 | 52.04 |
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.